Genomic data from NSCLC tumors reveals correlation between SHP-2 activity and PD-L1 expression and suggests synergy in combining SHP-2 and PD-1/PD-L1 inhibitors.

The identification of novel therapies, new strategies for combination of therapies, and repurposing of drugs approved for other indications are all important for continued progress in the fight against lung cancers. Antibodies that target immune checkpoints can unmask an immunologically hot tumor fr...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Keller J Toral, Mark A Wuenschel, Esther P Black
Format: article
Langue:EN
Publié: Public Library of Science (PLoS) 2021
Sujets:
R
Q
Accès en ligne:https://doaj.org/article/9d7801d876b04b58a06872bac8a15f68
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!